1 Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.
2 Philipps-University Marburg, Marburg, Germany.
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419846392. doi: 10.1177/1534735419846392.
The aim of this study was to assess the potential risks of interactions between biologically based complementary and alternative medication (BB-CAM) and conventional drugs during systemic therapy in breast and gynecological cancer patients by analyzing the actual CAM-drug combinations from individual patients' records.
From September 2014 to December 2014 and from February 2017 to May 2017, all patients (n = 717) undergoing systemic therapy at the Gynecologic Oncology Day Care Unit in the Gynecology and Obstetrics Department of the Technical University of Munich, Germany, were asked to participate in a questionnaire about all their medications. To assess the potential risk of CAM-drug interactions (CDIs), we initially utilized the Lexicomp drug interaction database. This assessment was then expanded with a systematic search of other digital databases, such as the National Center for Complementary and Integrative Health, Memorial Sloan Kettering Cancer Center, PubMed, and MEDLINE as well as the Cochrane Library.
Among 448 respondents, 74.1% reported using BB-CAM simultaneously with their systemic therapy. The assessment showed 1 patient with a potentially clinically relevant CDI, where the interaction was based on a self-medicated combination of Echinacea and cyclophosphamide. Furthermore, 81 patients (18.1%) were thought to have interactions because of a combination of BB-CAMs and cytochrome P450 3A4-metabolized anticancer drugs.
Our data demonstrated high overall use of BB-CAMs by cancer patients undergoing systemic therapy. The analyses showed only 1 clinically relevant CDI.
本研究旨在通过分析个体患者记录中的实际 CAM 药物组合，评估生物基础补充和替代药物 (BB-CAM) 与乳腺癌和妇科癌症患者全身治疗中常规药物之间相互作用的潜在风险。
2014 年 9 月至 12 月和 2017 年 2 月至 5 月，德国慕尼黑工业大学妇产科妇科肿瘤日间病房接受全身治疗的所有患者（n=717）均被要求参与一项关于他们所有药物的问卷。为评估 CAM 药物相互作用（CDI）的潜在风险，我们最初利用 Lexicomp 药物相互作用数据库进行评估。然后，通过对其他数字数据库（如国家补充与综合健康中心、纪念斯隆凯特琳癌症中心、PubMed 和 MEDLINE 以及 Cochrane 图书馆）进行系统搜索，扩展了这种评估。
在 448 名受访者中，74.1%的人报告同时使用 BB-CAM 进行全身治疗。评估显示 1 名患者存在潜在临床相关 CDI，该相互作用基于 Echinacea 和环磷酰胺的自我配药组合。此外，由于 BB-CAMs 和细胞色素 P450 3A4 代谢的抗癌药物的组合，81 名患者（18.1%）被认为存在相互作用。
我们的数据表明，接受全身治疗的癌症患者总体上高度使用 BB-CAMs。分析显示只有 1 种具有临床相关性的 CDI。
